Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.
Hamilton TC, et al. Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res. 43: 5379-5389, 1983. PubMed: 6604576
Hamilton TC, et al. Induction of progesterone receptor with 17beta-estradiol in human ovarian cancer. J. Clin. Endocrinol. Metab. 59: 561-563, 1984. PubMed: 6746867
Rogan AM, et al. Reversal of adriamycin resistance by verapamil in human ovarian cancer. Science 224: 994-996, 1984. PubMed: 6372095
Hamilton TC, et al. Characterization of a xenograft model of human ovarian carcinoma which produces ascites and intraabdominal carcinomatosis in mice. Cancer Res. 44: 5286-5290, 1984. PubMed: 6333272
Green JA, et al. Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion. Cancer Res. 44: 5427-5431, 1984. PubMed: 6488194
Caffrey PB, Frenkel GD. Selenite cytotoxicity in drug resistant and nonresistant human ovarian tumor cells. Cancer Res. 52: 4812-4816, 1992. PubMed: 1511444
Hamilton TC, et al. Experimental model systems of ovarian cancer: applications to the design and evaluation of new treatment approaches. Semin. Oncol. 11: 285-298, 1984. PubMed: 6385258
Godwin AK, et al. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc. Natl. Acad. Sci. USA 89: 3070-3074, 1992. PubMed: 1348364
Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc. Natl. Acad. Sci. USA 93: 136-140, 1996. PubMed: 8552591
Omelyanenko V, et al. HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. II. Processing in epithelial ovarian carcinoma cells in vitro. Int. J. Cancer 75: 600-608, 1998. PubMed: 9466663
Tumors developed within 21 days at 100% frequency (5/5).
